Nanoparticle-Mediated Diagnosis and Treatment of Human Disease
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: closed (20 April 2023) | Viewed by 10048
Special Issue Editor
Interests: nanomedicine; nanotoxicology; nanomediated immunoprophylaxis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Nanotechnology has opened up unique opportunities for diagnosis and treatment options due to particularities such as size, functionalization potential, as well as multimodal and synchronous mechanisms of action on living cells. This Special Edition is aiming to gather novel insights into the most recent directions toward nanotechnology-mediated diagnosis and treatment of human disease. Studies on nanopharmaceutic solutions designed for widely studied pathologies such as cancer, antimicrobial applications, and osteoregenerative applications are welcomed, together with more recent orientations, such as hematology, tissue regeneration, etc. Photothermal, nanotargeting, direct toxicity or other mechanistic approaches will equally find a place in this issue, with a special place given to theranostic applications. Evaluations of pharmacological biodistribution and bioavailability, pharmacokinetics, and toxicity for newly designed nanostructures, as part of human disease prevention and diagnosis are also welcomed. High-quality theoretical reviews opening the path to novel pharmaceutical applications of nanoparticles in the diagnosis and treatment of human disorders will also be an integral part of this issue.
Dr. Teodora Mocan
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanoparticles
- nanotechnology
- diagnosis
- treatment
- human disease
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.